Concord Biotech Limited (BOM:543960)

India flag India · Delayed Price · Currency is INR
1,199.15
-22.40 (-1.83%)
At close: Mar 2, 2026
-19.80%
Market Cap 125.63B
Revenue (ttm) 11.59B
Net Income (ttm) 3.13B
Shares Out n/a
EPS (ttm) 29.69
PE Ratio 40.20
Forward PE 30.96
Dividend 10.70 (0.89%)
Ex-Dividend Date Sep 3, 2025
Volume 50,613
Average Volume 123,020
Open 1,166.40
Previous Close 1,221.55
Day's Range 1,166.40 - 1,224.95
52-Week Range 1,056.75 - 2,149.90
Beta n/a
RSI 49.52
Earnings Date Feb 11, 2026

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,... [Read more]

Industry Pharmaceutical Preparations
Founded 1984
Employees 1,571
Stock Exchange Bombay Stock Exchange
Ticker Symbol 543960
Full Company Profile

Financial Performance

In fiscal year 2025, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.

Financial Statements

News

There is no news available yet.